A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency (Part B)
Latest Information Update: 30 Mar 2026
At a glance
- Drugs SR 604 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; First in man
- Sponsors Equilibra Bioscience
Most Recent Events
- 10 Mar 2026 Planned number of patients changed from 36 to 31.
- 10 Mar 2026 Planned End Date changed from 1 Jul 2026 to 28 Sep 2026.
- 10 Mar 2026 Planned primary completion date changed from 1 Jul 2026 to 28 Sep 2026.